Publications by Vidar Ormaasen
43 publications found
Original articles
Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection
NEJM Evid, 2 (3)
DOI 10.1056/evidoa2200302, PubMed 37213438
Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients
Proc Natl Acad Sci U S A, 117 (40), 25018-25025
DOI 10.1073/pnas.2010540117, PubMed 32943538
Encephalitis and aseptic meningitis: short-term and long-term outcome, quality of life and neuropsychological functioning
Sci Rep, 9 (1), 16158
DOI 10.1038/s41598-019-52570-2, PubMed 31695095
To what extent can clinical characteristics be used to distinguish encephalitis from encephalopathy of other causes? Results from a prospective observational study
BMC Infect Dis, 19 (1), 80
DOI 10.1186/s12879-018-3570-2, PubMed 30669985
High neopterin and IP-10 levels in cerebrospinal fluid are associated with neurotoxic tryptophan metabolites in acute central nervous system infections
J Neuroinflammation, 15 (1), 327
DOI 10.1186/s12974-018-1366-3, PubMed 30470234
Pneumococcal sepsis requiring mechanical ventilation: Cohort study in 38 patients with rapid progression to septic shock
Acta Anaesthesiol Scand, 62 (10), 1428-1435
DOI 10.1111/aas.13236, PubMed 30132782
Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?
AIDS, 32 (2), 205-215
DOI 10.1097/QAD.0000000000001684, PubMed 29112060
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
Clin Infect Dis, 62 (5), 655-663
DOI 10.1093/cid/civ963, PubMed 26620652
Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
J Int AIDS Soc, 17 (4 Suppl 3), 19810
DOI 10.7448/IAS.17.4.19810, PubMed 25397554
Deteriorating renal function and clinical outcomes in HIV-positive persons
AIDS, 28 (5), 727-37
DOI 10.1097/QAD.0000000000000134, PubMed 24983543
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial
Scand J Infect Dis, 45 (7), 543-51
DOI 10.3109/00365548.2012.756985, PubMed 23294034
External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients
AAPS J, 15 (2), 308-15
DOI 10.1208/s12248-012-9440-8, PubMed 23224752
Infectious encephalitis: a description of a Norwegian cohort
Scand J Infect Dis, 45 (3), 179-85
DOI 10.3109/00365548.2012.719634, PubMed 23113672
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients
J Pharmacokinet Pharmacodyn, 38 (6), 727-42
DOI 10.1007/s10928-011-9217-1, PubMed 21964996
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy
AAPS J, 13 (4), 598-605
DOI 10.1208/s12248-011-9299-0, PubMed 21913053
Amnesia following herpes simplex encephalitis: diffusion-tensor imaging uncovers reduced integrity of normal-appearing white matter
Radiology, 257 (3), 774-81
DOI 10.1148/radiol.10100179, PubMed 20935078
Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital
J Antimicrob Chemother, 65 (9), 1996-2000
DOI 10.1093/jac/dkq234, PubMed 20576637
Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients
AIDS Res Hum Retroviruses, 26 (5), 533-40
DOI 10.1089/aid.2009.0177, PubMed 20455766
HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania
Antivir Ther, 15 (7), 1003-9
DOI 10.3851/IMP1660, PubMed 21041915
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients
Eur J Clin Pharmacol, 66 (4), 349-57
DOI 10.1007/s00228-009-0763-z, PubMed 19967342
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
Retrovirology, 6, 49
DOI 10.1186/1742-4690-6-49, PubMed 19457244
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels
Eur J Clin Pharmacol, 64 (8), 775-81
DOI 10.1007/s00228-008-0492-8, PubMed 18458892
HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population
Scand J Infect Dis, 39 (1), 51-7
DOI 10.1080/00365540600904779, PubMed 17366013
[HIV/AIDS--from lethal syndrome to chronic disease]
Tidsskr Nor Laegeforen, 126 (23), 3121-4
PubMed 17160119
Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment
AIDS, 20 (6), 813-20
DOI 10.1097/01.aids.0000218544.54586.f1, PubMed 16549964
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes
J Acquir Immune Defic Syndr, 41 (3), 352-60
DOI 10.1097/01.qai.0000209899.05126.e4, PubMed 16540937
Serum concentrations of protease inhibitors as predictors of HIV-related clinical events in patients on antiretroviral therapy
Scand J Infect Dis, 38 (8), 650-3
DOI 10.1080/00365540600616993, PubMed 16857610
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
J Infect Dis, 192 (6), 958-66
DOI 10.1086/432916, PubMed 16107947
An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy
HIV Med, 5 (6), 400-6
DOI 10.1111/j.1468-1293.2004.00244.x, PubMed 15544691
Immunoglobulin levels amongst persons with and without human immunodeficiency virus type 1 infection in Uganda and Norway
Scand J Immunol, 59 (2), 203-8
DOI 10.1111/j.0300-9475.2004.01376.x, PubMed 14871298
Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection
Scand J Infect Dis, 35 (6-7), 383-8
DOI 10.1080/00365540310009716, PubMed 12953949
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts
J Infect Dis, 186 (2), 189-97
DOI 10.1086/341466, PubMed 12134254
[Severe falciparum malaria treated with exchange transfusion]
Tidsskr Nor Laegeforen, 122 (10), 999-1001
PubMed 12082710
A search for optimal criteria in initiating antiretroviral therapy in chronic human immunodeficiency virus infection focusing on CD4 count and HIV RNA
Scand J Infect Dis, 34 (12), 910-7
DOI 10.1080/0036554021000026957, PubMed 12587624
[Two cases of pneumococcal pericarditis]
Tidsskr Nor Laegeforen, 121 (15), 1801-3
PubMed 11464685
[Tick-borne encephalitis in Norway]
Tidsskr Nor Laegeforen, 121 (7), 807-9
PubMed 11301704
[Practical approach to otitis media with methicillin-resistant yellow Staphylococci]
Tidsskr Nor Laegeforen, 118 (26), 4091-2
PubMed 9844514
Review articles
[Tuberculosis among HIV-infected persons in Norway]
Tidsskr Nor Laegeforen, 121 (29), 3425-30
PubMed 11826791
[Antiviral therapy of HIV infection in adults]
Tidsskr Nor Laegeforen, 121 (29), 3414-20
PubMed 11826789
Other articles
[Experimental treatment for COVID-19 should be undertaken in randomised studies]
Tidsskr Nor Laegeforen, 140 (7)
DOI 10.4045/tidsskr.20.0282, PubMed 32378863
[Treatment of erythema migrans]
Tidsskr Nor Laegeforen, 128 (24), 2844
PubMed 19092956
Fatal subarachnoidal haemorrhage in a Norwegian traveller with dengue virus infection
Scand J Infect Dis, 39 (3), 272-4
DOI 10.1080/00365540600891307, PubMed 17366065
Theses
Studies on mortality, morbidity and predictors of clinical outcome in HIV infected individuals in Oslo: a cohort study 1983-2004
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 293, 1 b. (flere pag.)
BIBSYS 051512637, ISBN 82-8080-142-1